MMSI MERIT MEDICAL SYSTEMS INC Insider Trading

CCO Smith Christian Adam makes first open-market purchase: 1,626 shares as 5-insider buying cluster emerges.

Christian Adam Smith, Chief Commercial Officer at Merit Medical Systems, made his first open-market share purchase on open market, acquiring 1,626 shares as part of a broader buying wave that included five insiders purchasing within a two-week window. This marks a notable shift from his prior Form 4 activity, which consisted solely of stock-based compensation transactions—he is now writing a personal check rather than simply receiving equity through grants or exercises. The purchase occurs as the stock trades well below its 52-week high and down over the past three months, suggesting the CCO is buying into a period of weakness. Merit Medical itself remains a profitable company with growing revenue, providing a fundamentally sound backdrop for insider accumulation, though the stock's valuation is noticeably elevated relative to current earnings. The confluence of this insider's first voluntary buy, the concurrent cluster of insider purchases, and the company's underlying profitability makes this activity worth close attention.

Chief Legal Officer Lloyd Brian G. purchases 2,000 shares of MMSI as stock trades well below 52-week high amid cluster buying activity.

Lloyd Brian G., MMSI's Chief Legal Officer and Secretary, purchased shares for the first time as an open-market buyer in the 36-month record, a meaningful shift from his prior role as a seller. This purchase arrives while the stock trades substantially below its 52-week high and has declined over the past three months, yet the company remains profitable with growing revenue. What distinguishes this trade is the cluster pattern: four insiders bought within a two-week window, suggesting multiple executives saw value at these lower levels. Importantly, Lloyd's prior two sales showed conflicting timing signals—well-timed over a longer horizon as the stock fell, but one was poorly timed as the stock initially rose afterward—making his return to buying particularly noteworthy. This is not routine rebalancing but a regime change: a C-suite executive switching from net seller to buyer while the stock faces headwinds.

CEO Martha Goldberg Aronson purchased 2,000 shares at market price as stock trades well below recent highs, joining coordinated insider buying pattern.

Martha Goldberg Aronson, the company's President and CEO, is deploying personal capital to purchase shares while Merit Medical trades significantly below its recent highs—a convergence that suggests conviction rather than momentum chasing. Her purchase adds to a cluster of insider buying activity within the same window, indicating that multiple insiders are interpreting the pullback as an opportunity. As someone with direct operational knowledge of the business, her timing coincides with a company that remains solidly profitable with expanding revenue, even as the stock has pulled back sharply. This is particularly notable because the CEO has a measured history of share acquisitions—her prior purchase roughly two years ago signals consistency in her approach. The combination of leadership capital deployment, broad-based insider buying, and solid underlying financials during a period of price weakness frames this as strategic accumulation rather than opportunistic trading.

MMSI CFO Parra buys 1,500 shares as stock trades well below highs; reverses pattern of five consecutive sales with buy conviction at depressed valuation.

Raul Parra Jr., the company's CFO, has reversed course sharply: after five consecutive sales of MMSI stock dating back to November 2024, he is now buying—a notable shift in insider behavior. The timing underscores conviction: the stock is trading well below its recent highs and has declined meaningfully over the past three months, creating a window where capital deployment carries real conviction rather than momentum. Parra's prior sales showed mixed timing—some well-timed exits that preceded declines, but others where the stock rose after his sales—suggesting he does not have a perfect track record reading MMSI's direction. That context makes the current buy more significant: he is purchasing at prices substantially lower than the recent peak, and the company itself remains profitable with solid revenue growth, providing a fundamental floor beneath the purchase. This is a credible signal of insider confidence in valuation, though not a guaranteed predictor given his mixed prior history in this exact stock.

CHRO Michel Voigt bought 2,250 shares as stock trades well below 52-week highs; prior track record shows one poorly-timed sale.

Michel Voigt, the Chief Human Resources Officer of Merit Medical, made a substantial open-market purchase of shares at a time when the stock has declined meaningfully from its highs and fallen over a recent three-month window. The company itself remains solidly profitable with solid revenue growth, suggesting the operational fundamentals have not deteriorated despite the recent pullback. Voigt's prior track record includes one sale that preceded further gains in the stock, indicating he has not demonstrated strong timing on exits in this company. This buy represents his first open-market purchase on record—adding to zero prior buys—which makes the purchase notable as a reversal of his prior activity pattern. While a CHO's view may carry less weight than a CEO or CFO would, a C-suite executive buying during a downturn when holding no prior conviction buys could signal belief that the stock's recent weakness is overdone relative to the company's profitable operations.

Executive Chairman Lampropoulos sold 25,000 MMSI shares at $87.31; prior 4 same-ticker sells all well-timed (90d declines), current stock -21.0% from 52-week high.

Lampropoulos sold 25,000 shares (25.0K shares) of Merit Medical for $2,182,750.00, reducing holdings by 2.4% to 1,029,955 shares. His prior trade history at this ticker shows a consistent pattern: 4 of 4 prior sells at MMSI were well-timed at the 90-day mark, with returns of -11.1%, -3.9%, -1.7%, and -1.7% respectively, followed most recently by a June 2025 sale (-5.4% 90d return) and May 2025 sales (-5.3% and -1.7% 90d returns). The stock is currently trading -21.0% from its 52-week high of $110.29, suggesting the broader downtrend aligns with his historical selling pattern. While the cross-ticker track record shows 100.00% well-timed rate on 8 prior sells (avg 90d return -7.3%), the same-ticker history of repeated well-timed sales at MMSI specifically warrants attention to whether this sale reflects a known-pattern exit or a material change in conviction regarding the company's forward trajectory.

Executive Chairman Lampropoulos sells 20,000 shares of MMSI at $85.13; stock trades at $87.20 near 52-week mid-point, seller's 4 prior MMSI sales all negative 90-day performers.

Lampropoulos sold 20,000 shares (reducing holdings from 1,074,955 to 1,054,955) at $85.13, well below the current price of $87.20 and 20.9% below the 52-week high of $110.29. His prior trades at MMSI show a consistent pattern: all 4 prior measurable sales (on 2025-03-05, 2025-05-27, 2025-05-30, and 2025-06-05) yielded negative 90-day returns ranging from -5.3% to -9.1%, giving a 100% well-timed rate at this ticker. Across his broader open-market history across all tickers, he has executed 8 prior sells with an average 90-day return of -7.8% and a 90-day well-timed rate of 100%. The current sale follows this established pattern of selling before subsequent declines, though the stock's 30-day performance of +3.2% and near-midpoint valuation (between 52-week extremes) offer no immediate directional signal for this specific transaction.

CFO Parra sells 15,181 MMSI shares at $93.75; holds 24.2K shares post-trade; stock -15.8% from 52-week high.

Parra Raul Jr., as CFO and Treasurer, sold 15,181 shares worth $1,423,218.75, reducing his stake by 38.5% to 24.2K shares remaining. The sale occurred at $93.75, with the stock currently trading at $92.90 and down 15.8% from its 52-week high of $110.29, reflecting recent price weakness. His prior four sales at MMSI show mixed timing outcomes: one preceded a 90-day decline of 8.7%, but two others saw the stock rise 7.0% and 9.4% in the 90 days following the sale. The company's fundamentals remain solid with $355.4M quarterly revenue, $30.1M net income, and 7.9% annual growth, though the elevated P/E of 44.88 suggests current valuation is stretched relative to near-term earnings.

CEO Lampropoulos sold 10,000 MMSI shares at $95.19; stock now $94.84. Pattern shows 5 of 5 recent MMSI sales all preceded declines.

Fred P. Lampropoulos, President and CEO, sold 10,000 shares at $95.19 on 2025-06-05, reducing holdings from 1,056,028 to 1,046,028 shares (a -0.9% reduction). The current price of $94.84 is -14.0% from the 52-week high of $110.29, and the stock has declined 1.0% over 30 days and 3.6% over 90 days. Most notably, this sale is part of an aggressive series of five consecutive sales at MMSI beginning in early March, with three measurable historical sales showing 30-day declines of -10.8% to -11.1% and 90-day declines of -8.8% to -9.1%; all three prior completed MMSI sales were well-timed, as the stock fell after each transaction. The current sale arrived just days after two prior sales on 2025-05-30 and 2025-05-27 (timing for which remains unmeasurable), suggesting sustained execution of a large position reduction at this ticker. Given the consistent adverse price movement following his prior MMSI sales, the pattern warrants observation of whether the current transaction—executed at $95.19, above the current $94.84—precedes further weakness.

MMSI CEO Fred P. Lampropoulos sold 10,000 shares at $95.12 on 2025-05-30 (total $951.2K); stock now at $94.60, -14.2% from 52-week high.

Lampropoulos sold 10,000 shares at $95.12, reducing his holdings from 1.07M to 1.06M shares (a -0.9% reduction). His cross-ticker track record shows a 100.00% well-timed rate on 5 prior sells with an average 90-day return of -8.9%, indicating a consistent pattern of selling before subsequent declines. At MMSI specifically, his 4 prior measurable sells (all on 2025-03-05) were uniformly well-timed at the 90-day mark, each posting -10.8% or -11.1% downside in the 30- and 90-day periods following the sale. The current stock price of $94.60 is -14.2% from the 52-week high of $110.29 and has declined -1.1% over 30 days and -9.8% over 90 days since the transaction date—a pattern consistent with his prior execution at this ticker. Fundamentally, MMSI shows solid metrics (net income of $30.1M on revenue of $355.4M, +7.9% annual growth), but the elevated P/E of 45.70 and the insider's demonstrated ability to exit before declines warrant attention to whether valuation or forward guidance factors are driving this liquidity event.